Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Vopratelimab

😃Good
Catalog No. T77434Cas No. 2039148-04-2
Alias JTX 2011

Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. It exhibits anti-tumor immune effects and can improve metastatic non-small cell lung cancer.

Vopratelimab

Vopratelimab

😃Good
Catalog No. T77434Alias JTX 2011Cas No. 2039148-04-2
Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. It exhibits anti-tumor immune effects and can improve metastatic non-small cell lung cancer.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$413-In Stock
5 mg$1,070-In Stock
10 mg$1,650-In Stock
25 mg$2,460-In Stock
50 mg$3,320-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.34% (SEC-HPLC)
Contact us for more batch information

Product Introduction

Bioactivity
Description
Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. It exhibits anti-tumor immune effects and can improve metastatic non-small cell lung cancer.
In vitro
Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 days; CD4 T cells) activates primary human T cells, inducing the secretion of IFNγ, IL-17a, IL-10, IL-9, GM-CSF, TNFα, and IL-21[1].
In vivo
Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; twice weekly for 2 weeks) induces tumor regression in the Sa1/N syngeneic mouse tumor model[1].
SynonymsJTX 2011
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetICOS/CD278
Chemical Properties
Molecular Weight145.74 kDa
Cas No.2039148-04-2
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Vopratelimab | purchase Vopratelimab | Vopratelimab cost | order Vopratelimab | Vopratelimab in vivo | Vopratelimab in vitro | Vopratelimab molecular weight